Compare Regeneron Pharmaceuticals Inc (REGN) vs NEOS S&P 500 High Income ETF (SPYI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs NEOS S&P 500 High Income ETF — how do they compare? Regeneron Pharmaceuticals Inc trades at $746.54 (market cap $76.14B), while NEOS S&P 500 High Income ETF trades at $54.09 (market cap $12.50B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 6.1× NEOS S&P 500 High Income ETF's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while NEOS S&P 500 High Income ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and NEOS S&P 500 High Income ETF for 58 Days on average.
| REGN | SPYI | |
|---|---|---|
Market Cap | $76.14B | $12.50B |
Volume | 500,239 | 3,058,962 |
Sector | Health | Income / Options Overlay |
52-Week High | $852.03 | $54.42 |
52-Week Low | $557.73 | $47.98 |
Typical Hold Time | 107 Days | 58 Days |
Enterprise Value | $70.85B | — |
Dividend Yield | 0.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $739.57, down 0.34% with a bearish technical signal. The company maintains strong fundamentals with a 27.86% net income margin and consistent earnings beats. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront payments and milestone potential. Cash flow improved significantly in 2025 with $635 million net cash flow versus negative flows in prior years.
The stock presents a compelling investment case with strong profitability, positive analyst sentiment (69% buy ratings), and a $849.84 consensus price target offering 15% upside. Key risks include competitive pressures in ophthalmology drugs and reliance on key partnerships. The expanded Sanofi collaboration and promising clinical pipeline provide catalysts for growth.
SPYI trades at $53.86, down 0.28% with a bullish technical outlook supported by moving averages. The ETF generates consistent monthly dividends, with recent payouts around $0.53-0.54 per share. News coverage highlights SPYI's role in retirement income strategies but raises concerns about principal erosion from covered call strategies.
While SPYI offers attractive income generation for yield-seeking investors, the covered call strategy caps upside potential during market rallies. Principal preservation risks require careful monitoring, particularly for retirees depending on monthly distributions for income needs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About NEOS S&P 500 High Income ETF
SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →
